Sam Brusco, Associate Editor05.26.22
ManaMed has earned U.S. Food and Drug Administration (FDA) approval for its novel ManaSport ultrasound therapy device.
ManaSport offers pain relief and soft-tissue injury treatment via non-invasive pulsed ultrasound therapy at localized sites through ultrasound gel. According to the company, ManaSport is popular among athletes and sports professionals.
The device was approved for the following indications:
Intended for use under supervision, ManaSport is portable and rechargeable. A therapy session takes 20 minutes. A display provides instructions for use with a built-in calendar and safety features to prevent unintended operation.
"ManaMed will continue to design, develop, and innovate the entire medtech space,” the firm’s president and CEO Trevor Theriot told the press. “ManaSport demonstrates our commitment to invest in the future and expand our access to the entire continuum of care."
ManaSport offers pain relief and soft-tissue injury treatment via non-invasive pulsed ultrasound therapy at localized sites through ultrasound gel. According to the company, ManaSport is popular among athletes and sports professionals.
The device was approved for the following indications:
- Chronic pain relief.
- Muscle spasms and joint contractures.
- Relief from pain and joint contractures associated with adhesive capsulitis, bursitis with slight calcification, myositis, soft tissue injuries, and shortened tendons from past injuries and scar tissue.
- Relief from pain and muscle spasms resulting from capsular tightness and scarring.
- Increasing localized blood flow.
- Increasing range of motion of contracted joints with heat and stretch techniques.
Intended for use under supervision, ManaSport is portable and rechargeable. A therapy session takes 20 minutes. A display provides instructions for use with a built-in calendar and safety features to prevent unintended operation.
"ManaMed will continue to design, develop, and innovate the entire medtech space,” the firm’s president and CEO Trevor Theriot told the press. “ManaSport demonstrates our commitment to invest in the future and expand our access to the entire continuum of care."